Chairman of Guangzhou Xiangxue Precision Medical Technology Co., Ltd., President of Guangzhou Xiangxue Pharmaceutical Life Science Center, Research Fellow of Guangzhou Institute of Biomedicine and Health (GIBH), Chinese Academy of Sciences, and National Key Program of Respiratory Diseases, Guangzhou, China Laboratory researcher. Dr. Li graduated from the Hunan Medical University (Xiangya) and received his Ph.D. from the University of Leicester College of Life Sciences. He spent 20 years in the UK doing antibody and T cell receptor research. His main research was focused on developing TCR-based immunotherapy. His works were published in Nature Biotechnology, Nature Medicine, JBC, Molecular Cancer Therapy, and so on.

Dr. Gong received his Ph.D. from the University of Wales (Swansea). He has accumulated nearly 20 years of research and development experience after working in proteomic and monoclonal antibody biotechnology companies, biopharmaceutical companies in the UK. Before coming back to China, he was the chief scientist at UCB Pharma, responsible for the development of the monoclonal antibody, Cimzia, for arthritis, which generated more than 1 billion revenue in Euro in 2015. Dr. Gong has a tremendous amount experience in developing Mass Spectrometry of proteins, protein structures, protein-protein interactions, characterization analysis of protein drugs, development and quality control of protein drugs, bioengineering and so on. His works were published in J. Trans. Med., Current Proteomics, J. Str. Bio., JBC, etc.